The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
RIDAURA auranofin 3mg capsules (Canada)
Section 19A approved medicine
RIDAURA auranofin 3mg capsules (Canada)
Section 19A approval holder
Boucher & Muir Pty Ltd T/A Advanz Pharma ABN 58 000 140 474
Phone
02 9431 6333
Approved until
Status
Current
Medicines in short supply/unavailable
RIDAURA auranofin 3mg tablet bottle - ARTG 13000
Indication(s)
Adjunctive treatment of active classical or definite rheumatoid arthritis in adults who have an insufficient therapeutic response to, or are intolerant of, an adequate trial of a baseline therapeutic program, including among other measures, full doses of one or more non-steroidal anti-inflammatory drugs. RIDAURA is not indicated in non-rheumatoid arthropathies such as osteoarthrosis. RIDAURA should be added to a comprehensive baseline therapeutic program.
Additional information
Images
